Published in Hypertension on October 01, 2002
Nitric oxide and peroxynitrite in health and disease. Physiol Rev (2007) 15.49
Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol (2004) 2.46
Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res (2008) 1.76
The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia. Endocrinology (2008) 1.61
Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation. Hypertension (2005) 1.60
Effects of tempol on renal angiotensinogen production in Dahl salt-sensitive rats. Biochem Biophys Res Commun (2004) 1.41
Aldosterone-Induced Vascular Remodeling and Endothelial Dysfunction Require Functional Angiotensin Type 1a Receptors. Hypertension (2016) 1.40
Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol (2011) 1.38
Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol (2010) 1.35
Vascular endothelial function and hypertension: insights and directions. Curr Hypertens Rep (2010) 1.34
Interleukin-10 released by CD4(+)CD25(+) natural regulatory T cells improves microvascular endothelial function through inhibition of NADPH oxidase activity in hypertensive mice. Arterioscler Thromb Vasc Biol (2011) 1.29
Chronic high pressure-induced arterial oxidative stress: involvement of protein kinase C-dependent NAD(P)H oxidase and local renin-angiotensin system. Am J Pathol (2004) 1.28
Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats. Microvasc Res (2007) 1.23
Central interactions of aldosterone and angiotensin II in aldosterone- and angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol (2010) 1.21
Targeting NADPH oxidases in vascular pharmacology. Vascul Pharmacol (2012) 1.20
Adiponectin deficiency, diastolic dysfunction, and diastolic heart failure. Endocrinology (2009) 1.16
Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. Am J Physiol Endocrinol Metab (2008) 1.15
Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes (2010) 1.12
Exercise in the metabolic syndrome. Oxid Med Cell Longev (2012) 1.11
Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. Circ Res (2003) 1.10
Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Br J Pharmacol (2005) 1.10
Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol (2008) 1.08
Redox-sensitive signaling by angiotensin II involves oxidative inactivation and blunted phosphorylation of protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells from SHR. Circ Res (2008) 1.06
Aldosterone and arterial hypertension. Nat Rev Endocrinol (2009) 1.06
Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev (2005) 1.05
Vascular inflammation and endothelial dysfunction in experimental hypertension. Int J Hypertens (2011) 1.03
Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane A2 and prostacyclin. Br J Pharmacol (2008) 1.03
The mineralocorticoid receptor and oxidative stress. Heart Fail Rev (2005) 0.98
Angiotensin II, Aldosterone, and Anti-Inflammatory Lymphocytes: Interplay and Therapeutic Opportunities. Int J Hypertens (2012) 0.97
Why are mineralocorticoid receptor antagonists cardioprotective? Naunyn Schmiedebergs Arch Pharmacol (2006) 0.97
Oxidative Stress and Vascular Damage in Hypertension: Role of Angiotensin II. Int J Hypertens (2011) 0.96
Fibrosis in hypertensive heart disease: molecular pathways and cardioprotective strategies. J Hypertens (2010) 0.96
Macro- and micronutrients in African-Americans with heart failure. Heart Fail Rev (2006) 0.95
Endothelium-derived Relaxing Factors of Small Resistance Arteries in Hypertension. Toxicol Res (2014) 0.95
Eplerenone suppresses aldosterone/ salt-induced expression of NOX-4. J Renin Angiotensin Aldosterone Syst (2011) 0.94
Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? Pflugers Arch (2008) 0.92
Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol (2010) 0.92
Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications. Br J Pharmacol (2013) 0.92
Macro- and micronutrient dyshomeostasis in the adverse structural remodelling of myocardium. Cardiovasc Res (2008) 0.91
Olmesartan improves endothelin-induced hypertension and oxidative stress in rats. Hypertens Res (2004) 0.90
Tempol, a superoxide dismutase mimetic, prevents cerebral vessel remodeling in hypertensive rats. Microvasc Res (2010) 0.89
Aldosterone induces mesangial cell apoptosis both in vivo and in vitro. Am J Physiol Renal Physiol (2008) 0.89
Eplerenone prevents salt-induced vascular stiffness in Zucker diabetic fatty rats: a preliminary report. Cardiovasc Diabetol (2011) 0.89
Congestive heart failure is a systemic illness: a role for minerals and micronutrients. Clin Med Res (2007) 0.87
Smooth muscle cell mineralocorticoid receptors: role in vascular function and contribution to cardiovascular disease. Pflugers Arch (2013) 0.86
Role of mineralocorticoid receptor antagonists in cardiovascular disease. Circ Res (2015) 0.85
Cellular and molecular pathways to myocardial necrosis and replacement fibrosis. Heart Fail Rev (2011) 0.83
Synergistic vascular protective effects of combined low doses of PPARalpha and PPARgamma activators in angiotensin II-induced hypertension in rats. Br J Pharmacol (2007) 0.83
Chronic aldosterone administration causes Nox2-mediated increases in reactive oxygen species production and endothelial dysfunction in the cerebral circulation. J Hypertens (2014) 0.82
Aldosterone enhances IGF-I-mediated signaling and biological function in vascular smooth muscle cells. Endocrinology (2010) 0.82
Aldosterone: good guy or bad guy in cerebrovascular disease? Trends Endocrinol Metab (2005) 0.80
Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. Vasc Health Risk Manag (2011) 0.79
Renal denervation attenuates aldosterone expression and associated cardiovascular pathophysiology in angiotensin II-induced hypertension. Oncotarget (2016) 0.79
Changes in cardiopulmonary reserve and peripheral arterial function concomitantly with subclinical inflammation and oxidative stress in patients with heart failure with preserved ejection fraction. Int J Vasc Med (2014) 0.79
Aldosterone Receptor Antagonism Reduces Urinary C-Reactive Protein Excretion in Angiotensin II-Infused, Hypertensive Rats. J Am Soc Hypertens (2010) 0.79
Breakthrough in heart failure with preserved ejection fraction: are we there yet? Korean J Intern Med (2015) 0.78
Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling. Front Physiol (2015) 0.78
Vascular dysfunction as target organ damage in animal models of hypertension. Int J Hypertens (2012) 0.77
Eplerenone suppresses salt-induced vascular endothelial growth factor expression in the kidney. Kidney Blood Press Res (2010) 0.77
Late gestational hypoxia and a postnatal high salt diet programs endothelial dysfunction and arterial stiffness in adult mouse offspring. J Physiol (2015) 0.77
Rosuvastatin prevents angiotensin II-induced vascular changes by inhibition of NAD(P)H oxidase and COX-1. Br J Pharmacol (2013) 0.77
Does the sympathetic nervous system contribute to the pathophysiology of metabolic syndrome? Front Physiol (2015) 0.76
Microvascular NADPH oxidase in health and disease. Free Radic Biol Med (2017) 0.75
Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats. Clin Exp Pharmacol Physiol (2015) 0.75
Short daily versus conventional hemodialysis for hypertensive patients: a randomized cross-over study. PLoS One (2014) 0.75
Myocardial remodeling in low-renin hypertension: molecular pathways to cellular injury in relative aldosteronism. Curr Hypertens Rep (2009) 0.75
Unmasked renal impairment and prolonged hyperkalemia after unilateral adrenalectomy for primary aldosteronism coexisting with primary hyperparathyroidism: report of a case. Surg Today (2013) 0.75
Eplerenone inhibits aldosterone-induced renal expression of cyclooxygenase. J Renin Angiotensin Aldosterone Syst (2012) 0.75
Genomic and rapid effects of aldosterone: what we know and do not know thus far. Heart Fail Rev (2016) 0.75
Association of Prooxidant-Antioxidant Balance with Clinical and Laboratory Parameters and Its Relation to Different Drug Regimens in Polycystic Ovary Syndrome Women with Normal BMI. Indian J Clin Biochem (2016) 0.75
30 YEARS OF THE MINERALOCORTICOID RECEPTOR: The role of the mineralocorticoid receptor in the vasculature. J Endocrinol (2017) 0.75
The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol (2010) 5.54
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med (2003) 4.08
Endothelial dysfunction. J Am Soc Nephrol (2004) 3.18
NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care (2008) 3.07
Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) (2013) 2.94
Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens (2014) 2.82
Redox signaling in hypertension. Cardiovasc Res (2006) 2.37
Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis. J Am Coll Cardiol (2013) 2.29
Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res (2002) 2.27
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2005) 2.13
Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension (2006) 2.12
Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation (2002) 2.07
T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension (2011) 2.03
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Can J Cardiol (2005) 2.03
Inflammation in hypertension. Curr Opin Nephrol Hypertens (2006) 2.01
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2007) 2.01
Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association. Hypertension (2015) 2.01
Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci (2008) 1.97
Endothelin-1-induced oxidative stress in DOCA-salt hypertension involves NADPH-oxidase-independent mechanisms. Clin Sci (Lond) (2006) 1.87
The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2012) 1.86
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol (2013) 1.85
Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus. Circulation (2008) 1.82
Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension (2006) 1.80
Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond) (2007) 1.79
NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation (2013) 1.78
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol (2006) 1.67
Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system. Am J Hypertens (2004) 1.67
Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation (2004) 1.65
Differential regulation of thioredoxin and NAD(P)H oxidase by angiotensin II in male and female mice. J Hypertens (2007) 1.65
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2009) 1.64
Neonatal oxygen exposure in rats leads to cardiovascular and renal alterations in adulthood. Hypertension (2008) 1.64
Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension (2012) 1.63
Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res (2008) 1.59
Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension (2007) 1.58
Oxidases and peroxidases in cardiovascular and lung disease: new concepts in reactive oxygen species signaling. Free Radic Biol Med (2011) 1.56
Oxidative stress and hypertension: current concepts. Curr Hypertens Rep (2010) 1.54
Endothelial nitric oxide synthase uncoupling and perivascular adipose oxidative stress and inflammation contribute to vascular dysfunction in a rodent model of metabolic syndrome. Hypertension (2009) 1.54
Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis. J Hypertens (2012) 1.52
Inactivation of endothelial proprotein convertase 5/6 decreases collagen deposition in the cardiovascular system: role of fibroblast autophagy. J Mol Med (Berl) (2011) 1.51
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2007) 1.49
The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy. Can J Cardiol (2002) 1.49
Loss of Lkb1 in adult beta cells increases beta cell mass and enhances glucose tolerance in mice. Cell Metab (2009) 1.47
Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension (2005) 1.47
Human cord blood CD133+ cells exacerbate ischemic acute kidney injury in mice. Nephrol Dial Transplant (2012) 1.46
The World Hypertension League and International Society of Hypertension call on governments, nongovernmental organizations, and the food industry to work to reduce dietary sodium. J Clin Hypertens (Greenwich) (2014) 1.44
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2010) 1.44
Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats. J Hypertens (2005) 1.43
Deficiency of T-regulatory cells exaggerates angiotensin II-induced microvascular injury by enhancing immune responses. J Hypertens (2016) 1.43
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. Can J Cardiol (2009) 1.42
Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats. J Hypertens (2002) 1.42
Effects of low dietary magnesium intake on development of hypertension in stroke-prone spontaneously hypertensive rats: role of reactive oxygen species. J Hypertens (2002) 1.42
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2006) 1.42
Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronectin synthesis in mesangial cells. Diabetes (2002) 1.42
Microparticles: biomarkers and beyond. Clin Sci (Lond) (2013) 1.41
Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. Hypertension (2006) 1.40
Optimum blood pressure target after lacunar stroke: con side of the argument. Hypertension (2014) 1.39
Novel drugs targeting hypertension: renin inhibitors and beyond. J Cardiovasc Pharmacol (2007) 1.39
The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2011) 1.38
Myocyte growth, repair, and oxidative stress following pediatric heart transplantation. Pediatr Transplant (2014) 1.37
Transient receptor potential melastatin 7 ion channels regulate magnesium homeostasis in vascular smooth muscle cells: role of angiotensin II. Circ Res (2004) 1.36
Molecular mechanisms of hypertension--reactive oxygen species and antioxidants: a basic science update for the clinician. Can J Cardiol (2012) 1.36
T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension (2011) 1.35
Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol (2010) 1.35
Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. J Hypertens (2004) 1.34
Oxidative stress, Noxs, and hypertension: experimental evidence and clinical controversies. Ann Med (2012) 1.33
A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev (2012) 1.31
Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol (2003) 1.30